Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Current Taxes (2023 - 2026)

Catalyst Pharmaceuticals filings provide 4 years of Current Taxes readings, the most recent being $19.6 million for Q1 2026.

  • On a quarterly basis, Current Taxes rose 77.02% to $19.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $19.6 million, a 77.02% increase, with the full-year FY2025 number at $1.4 million, up 56.15% from a year prior.
  • Current Taxes hit $19.6 million in Q1 2026 for Catalyst Pharmaceuticals, up from $1.4 million in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $19.6 million in Q1 2026 to a low of $15000.0 in Q2 2024.
  • Median Current Taxes over the past 4 years was $811500.0 (2023), compared with a mean of $4.4 million.
  • Biggest five-year swings in Current Taxes: rose 22.63% in 2024 and later skyrocketed 2826.67% in 2025.
  • Catalyst Pharmaceuticals' Current Taxes stood at $729000.0 in 2023, then rose by 22.63% to $894000.0 in 2024, then surged by 56.15% to $1.4 million in 2025, then soared by 1305.87% to $19.6 million in 2026.
  • The last three reported values for Current Taxes were $19.6 million (Q1 2026), $1.4 million (Q4 2025), and $710000.0 (Q3 2025) per Business Quant data.